Cargando…

Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer

AZD6244 (ARRY-142886), a highly selective MAPK-ERK kinase inhibitor, has shown excellent clinical efficacy in many tumors. However, the anti-tumor and anti-angiogenesis efficacy of AZD6244 on gastric cancer has not been well characterized. In this study, high p-ERK expression was associated with adv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Jin-Hang, Wang, Chun-Hui, Tong, Huan, Wen, Shi-Lei, Huang, Zhi-Yin, Tang, Cheng-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644956/ https://www.ncbi.nlm.nih.gov/pubmed/26567773 http://dx.doi.org/10.1038/srep16382

Ejemplares similares

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
por: Gao, Jin-Hang, et al.
Publicado: (2022)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
por: Desar, Ingrid M. E., et al.
Publicado: (2012)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
por: Carvajal, Richard D., et al.
Publicado: (2015)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
por: Leijen, Suzanne, et al.
Publicado: (2011)

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2018)

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2022)

Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation()
por: Grasso, Silvina, et al.
Publicado: (2014)

Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells
por: Lee, Miso, et al.
Publicado: (2019)

Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation
por: Zhang, Qin, et al.
Publicado: (2018)

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
por: Qu, Yiqing, et al.
Publicado: (2014)

Effects of a checkpoint kinase inhibitor, AZD7762, on tumor suppression and bone remodeling
por: Wang, Luqi, et al.
Publicado: (2018)

Roles of Polo-like kinase 3 in suppressing tumor angiogenesis
por: Xu, Dazhong, et al.
Publicado: (2012)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
por: Kim, Ki Hyung, et al.
Publicado: (2009)

Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study
por: MacRae, Calum A., et al.
Publicado: (2022)

AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways
por: Yin, Wei, et al.
Publicado: (2021)

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma
por: Talebpoor, Maryam, et al.
Publicado: (2022)

Ghrelin Stimulates Endothelial Cells Angiogenesis through Extracellular Regulated Protein Kinases (ERK) Signaling Pathway
por: Wang, Jun, et al.
Publicado: (2018)

NPNT is Expressed by Osteoblasts and Mediates Angiogenesis via the Activation of Extracellular Signal-regulated Kinase
por: Kuek, Vincent, et al.
Publicado: (2016)

Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer
por: Chen, Shuo, et al.
Publicado: (2016)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
por: Zhu, Jian, et al.
Publicado: (2019)

Corrigendum: NPNT is Expressed by Osteoblasts and Mediates Angiogenesis via the Activation of Extracellular Signal-regulated Kinase
por: Kuek, Vincent, et al.
Publicado: (2016)

Hyperoxia Disrupts Extracellular Signal-Regulated Kinases 1/2-Induced Angiogenesis in the Developing Lungs
por: Menon, Renuka T., et al.
Publicado: (2018)

Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
por: Johnson, Melissa, et al.
Publicado: (2022)

Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
por: Chang, Jinjia, et al.
Publicado: (2014)

Endothelial receptor tyrosine kinases involved in angiogenesis
Publicado: (1995)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Revisiting PI3-kinase signalling in angiogenesis
por: Kobialka, Piotr, et al.
Publicado: (2019)

Trop2 inhibition suppresses the proliferation and invasion of laryngeal carcinoma cells via the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway
por: WANG, XU-DONG, et al.
Publicado: (2015)

Sucrose-induced Receptor Kinase 1 is Modulated by an Interacting Kinase with Short Extracellular Domain
por: Wu, Xu Na, et al.
Publicado: (2019)

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()
por: Li, Haifu, et al.
Publicado: (2014)

Cordycepin Suppresses Endothelial Cell Proliferation, Migration, Angiogenesis, and Tumor Growth by Regulating Focal Adhesion Kinase and p53
por: Lin, Yi-Ting, et al.
Publicado: (2019)

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
por: Davis, S. Lindsey, et al.
Publicado: (2022)

Roles of Extracellular Signal‐regulated Kinase 1/2 and p38 Mitogen‐activated Protein Kinase in the Signal Transduction of Basic Fibroblast Growth Factor in Endothelial Cells during Angiogenesis
por: Tanaka, Katsuhiro, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_2c3t76t2p96oup4b9khkc5aoao